U.S. markets closed
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • Dow 30

    31,496.30
    +572.16 (+1.85%)
     
  • Nasdaq

    12,920.15
    +196.68 (+1.55%)
     
  • Russell 2000

    2,192.21
    +45.29 (+2.11%)
     
  • Crude Oil

    66.28
    +2.45 (+3.84%)
     
  • Gold

    1,698.20
    -2.50 (-0.15%)
     
  • Silver

    25.30
    -0.17 (-0.65%)
     
  • EUR/USD

    1.1925
    -0.0054 (-0.45%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • GBP/USD

    1.3827
    -0.0067 (-0.48%)
     
  • USD/JPY

    108.2450
    +0.2690 (+0.25%)
     
  • BTC-USD

    49,014.70
    +783.15 (+1.62%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.78 (-0.23%)
     

GW Pharmaceuticals Q2 Earnings Preview

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Newsdesk
  • Oops!
    Something went wrong.
    Please try again later.

GW Pharmaceuticals (NASDAQ: GWPH) will be releasing its next round of earnings this Monday, May 6. For all of the relevant information, here is your guide for Monday's second-quarter earnings announcement.

Earnings and Revenue

Based on management's projections, GW Pharmaceuticals analysts modeled for a loss of $1.27 per share on sales of $17.33 million.

GW Pharmaceuticals reported a per-share loss of $3.12 when it published results during the same quarter last year. Sales in that period totaled $3.35 million. Analysts estimate would represent a 59.29 percent decrease in the company's earnings. Revenue would be up 417.16 percent on a year-over-year basis. GW Pharmaceuticals's reported EPS has stacked up against analyst estimates in the past like this:

View more earnings on GWPH

Quarter

Q1 2019

Q4 2018

Q3 2018

Q2 2018

EPS Estimate

-2.9

-2.46

-2.67

-2.48

EPS Actual

-0.2

-0.23

-1.26

-3.12

Stock Performance

Over the last 52-week period, shares are up 27.55 percent. Given that these returns are generally positive, long-term shareholders can relax going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.

Over the past 90 days, analysts have generally adjusted their estimates higher for EPS and revenues. The average rating by analysts on GW Pharmaceuticals stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.

Conference Call

GW Pharmaceuticals's conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here: https://www.webcaster4.com/Webcast/Page/2013/30400

See more from Benzinga

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.